NCT00502385View on ClinicalTrials.gov

Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

PHASE1CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

April 30, 2004

Conditions

LeukaemiaMyelocyticAcute

Interventions

DRUG

AZD2171

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY